Human Blood Plasma Fractionation Market Size, Share, Growth, and Industry Analysis, By Type (Immune Globulin,Coagulation Factor,Albumin,Others), By Application (Hospital,Retail Pharmacy,Others), Regional Insights and Forecast to 2035

Unique Information about the Human Blood Plasma Fractionation Market

Global Human Blood Plasma Fractionation market size is projected at USD 37784.11 million in 2026 and is expected to hit USD 73197.69 million by 2035 with a CAGR of 7.6%.

The Human Blood Plasma Fractionation Market represents a critical segment of the global biopharmaceutical industry, focusing on the separation of plasma proteins into therapeutic components such as albumin, immunoglobulins, and clotting factors. Globally, more than 55 million liters of plasma are processed annually for fractionation across approximately 70 licensed plasma fractionation facilities. Around 65% of fractionated plasma products are used for immunology and neurology treatments, while 20%–25% are used in hematology applications. More than 400 plasma-derived medicinal products are approved globally. Plasma-derived therapies are used in treatment of over 100 rare diseases, including primary immunodeficiency affecting 6 million people worldwide.

The United States dominates plasma collection and fractionation infrastructure, accounting for nearly 70% of the world’s plasma supply. The country operates more than 1,000 plasma collection centers, with approximately 50 million liters of plasma collected annually. Plasma-derived therapies are used by over 300,000 U.S. patients suffering from immune deficiencies, hemophilia, and neurological disorders. The U.S. also hosts over 20 industrial-scale fractionation plants, processing plasma into products such as albumin, IVIG, and coagulation factors. Nearly 85% of U.S. plasma donations come from compensated donors, enabling the country to supply more than 60% of the global plasma fractionation demand.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: Approximately 72% demand increase in immunoglobulin therapies, 48% rise in neurological treatments, 41% rare disease diagnoses, 36% plasma collection expansion, and 52% hospital utilization.
• Major Market Restraint: Nearly 34% operational cost pressure, 29% regulatory compliance burden, 22% plasma donor shortage, 18% cold-chain logistics challenges, and 27% manufacturing complexity impact expansion.
• Emerging Trends: Around 44% growth in immunoglobulin demand, 38% recombinant technology adoption, 33% automated fractionation expansion, 26% purification efficiency improvements, and 31% digital donor screening.
• Regional Leadership: North America holds about 46% market share, Europe 28%, Asia-Pacific 19%, Middle East & Africa 4%, and Latin America 3%.
• Competitive Landscape: Top 3 companies control 58% share, top 5 exceed 70% capacity, with 35 manufacturers, 90 facilities, and 150 global distribution partnerships.
• Market Segmentation: Immunoglobulins represent 44% share, albumin 26%, coagulation factors 21%, and other plasma proteins 9% within therapeutic plasma product segmentation.
• Recent Development: From 2023–2025, 28% plasma center expansion, 22% capacity upgrades, 35% immunoglobulin production growth, 18% purification improvements, and 24% clinical trial increase.

Human Blood Plasma Fractionation Market Latest Trends

The Human Blood Plasma Fractionation Market Trends highlight significant advancements in both technology and therapeutic applications. Immunoglobulin therapies remain the largest segment of plasma-derived treatments, accounting for approximately 44% of total plasma product consumption globally. Demand for intravenous immunoglobulin (IVIG) has increased by more than 50% over the last decade, largely due to rising diagnosis rates of autoimmune and neurological diseases. Globally, more than 350,000 patients receive IVIG therapies each year for conditions such as chronic inflammatory demyelinating polyneuropathy, Guillain-Barré syndrome, and primary immunodeficiency disorders. Increased awareness of rare diseases has also led to nearly 40% growth in immunodeficiency diagnoses in the past ten years, supporting stronger demand for plasma-derived immunoglobulins.

Technological innovation is another key trend shaping the Human Blood Plasma Fractionation Market Outlook. Modern fractionation plants now use 6–8 purification stages, compared with 3–4 stages used in earlier manufacturing processes, improving protein purity levels above 99%. Approximately 60% of newly established fractionation facilities use automated chromatography-based separation technologies that improve yield and production efficiency. Meanwhile, cold ethanol fractionation remains widely used, accounting for nearly 70% of global plasma processing methods, while advanced chromatographic purification contributes around 30%. Expansion of plasma collection infrastructure is also accelerating market development. The number of global plasma donation centers increased from approximately 1,200 facilities in 2018 to more than 1,600 centers by 2024, representing a 33% increase in collection capacity. Countries such as China expanded domestic plasma collection capacity by nearly 40% between 2020 and 2024, strengthening local manufacturing of albumin and immunoglobulin products.

Human Blood Plasma Fractionation Market Dynamics

DRIVER

"Rising demand for plasma-derived therapeutics"

The Human Blood Plasma Fractionation Market Growth is significantly driven by rising demand for plasma-derived medicinal products used in immunology, neurology, and hematology. Globally, more than 10 million patients require plasma-derived therapies annually. Primary immunodeficiency diseases affect approximately 1 in 1,200 individuals, increasing demand for immunoglobulin therapies. The use of albumin in critical care has expanded by nearly 30% in intensive care units for treating burns, trauma, and liver disease. Hemophilia treatment also relies heavily on plasma-derived clotting factors, with over 400,000 hemophilia patients worldwide requiring regular therapy. In addition, aging populations contribute to increased demand, as individuals aged 65 years and older represent nearly 18% of immunoglobulin therapy recipients.

RESTRAINT

"Limited plasma donor availability in several regions"

Despite strong demand, plasma supply limitations restrict Human Blood Plasma Fractionation Market expansion. Approximately 80% of global plasma donations originate from only 5 countries, creating supply concentration risks. Several European countries rely on imports for more than 60% of plasma supply, while Asia imports approximately 45% of its plasma-derived therapies. Donation regulations also affect supply, as voluntary donation programs in many regions produce 30–40% lower plasma volumes compared to compensated systems. Additionally, plasma collection requires specialized equipment and screening protocols, with each donor screening involving 20–25 laboratory tests, increasing operational costs and slowing expansion in developing markets.

OPPORTUNITY

"Expansion of rare disease treatment applications"

The Human Blood Plasma Fractionation Market Opportunities are expanding due to increasing use of plasma-derived products for rare diseases. More than 7,000 rare diseases have been identified globally, and approximately 5%–7% require plasma-derived therapies. New clinical research is exploring plasma proteins for neurological conditions such as Alzheimer’s disease and autoimmune encephalitis. Over 120 clinical trials involving plasma-derived immunoglobulin therapies were registered globally between 2022 and 2025. Additionally, emerging markets in Asia-Pacific increased plasma collection capacity by 35% between 2020 and 2024, providing opportunities for regional manufacturing expansion and improved treatment accessibility.

CHALLENGE

"Complex manufacturing and purification processes"

Plasma fractionation involves highly complex manufacturing processes, creating operational challenges in the Human Blood Plasma Fractionation Industry Analysis. Each batch of plasma-derived products requires processing of approximately 10,000–15,000 plasma donations to produce therapeutic proteins. Fractionation processes typically involve 8–12 purification stages, including precipitation, filtration, chromatography, and viral inactivation. Maintaining strict safety protocols is essential, as manufacturers must implement multiple pathogen reduction steps to eliminate viruses such as hepatitis B, hepatitis C, and HIV. Facilities must also comply with over 150 regulatory quality standards, and production cycles can extend to 7–12 months, limiting rapid supply expansion.

Segmentation Analysis

The Human Blood Plasma Fractionation Market Analysis is segmented by type and application. Product types include immune globulin, coagulation factor, albumin, and other plasma proteins. Immunoglobulins account for nearly 44% of product demand, albumin represents 26%, and coagulation factors contribute 21% of global consumption. Applications include hospitals, retail pharmacies, and other healthcare facilities. Hospitals dominate with approximately 62% market share, followed by retail pharmacies at 25%, while other channels represent 13% of distribution within the Human Blood Plasma Fractionation Market Research Report.

Download FREE Sample to learn more about this report.

By Type

Immune Globulin: Immune globulin represents the largest segment of the Human Blood Plasma Fractionation Market Share, accounting for approximately 44% of global plasma-derived therapy demand. Around 200 tons of immunoglobulin products are produced annually worldwide. Intravenous immunoglobulin (IVIG) treatments are used to manage over 50 immune-related disorders, including primary immunodeficiency and autoimmune neuropathies. Approximately 70% of immunoglobulin therapies are administered intravenously, while 30% are delivered via subcutaneous methods. In the United States alone, more than 150,000 patients receive immunoglobulin therapy annually. Increased diagnostic awareness has resulted in 40% higher identification rates of immunodeficiency diseases in the past decade.

Coagulation Factor: Coagulation factors account for nearly 21% of the Human Blood Plasma Fractionation Market Size and are essential for treating bleeding disorders including hemophilia A and hemophilia B. Globally, more than 400,000 hemophilia patients depend on coagulation factor therapies for regular treatment and emergency bleeding control. Plasma-derived factor VIII and factor IX concentrates are distributed in more than 120 countries through specialized treatment programs. Around 75% of hemophilia treatment centers still rely on plasma-derived factors where recombinant alternatives remain limited. Worldwide fractionation facilities collectively manufacture nearly 150 million international units (IU) of clotting factor concentrates annually for therapeutic use.

Albumin: Albumin represents approximately 26% of the Human Blood Plasma Fractionation Market Insights, making it one of the most widely utilized plasma proteins in clinical care. Global production of albumin exceeds 500 tons annually, primarily used in hospitals to treat trauma, liver cirrhosis, severe burns, and critical care complications. Nearly 65% of albumin consumption occurs in intensive care and emergency departments. China accounts for about 50% of global albumin demand, driven by high rates of liver disease and hospital admissions. Albumin therapy is also used in more than 30% of liver transplantation procedures worldwide to stabilize blood volume and protein balance.

Others: Other plasma-derived proteins contribute nearly 9% of the Human Blood Plasma Fractionation Market Growth and include specialized therapies such as alpha-1 antitrypsin, fibrinogen, and C1 esterase inhibitors. Alpha-1 antitrypsin deficiency affects about 1 in 2,500 individuals globally, creating continuous demand for replacement therapies. Fibrinogen products are frequently used in trauma care and surgical bleeding management, accounting for roughly 15% of emergency blood protein treatments in advanced healthcare systems. More than 80 countries utilize these specialized plasma proteins for treating rare genetic conditions, immune disorders, and acute surgical complications within modern healthcare systems.

By Application

Hospital: Hospitals hold the largest share in the Human Blood Plasma Fractionation Market Forecast, accounting for nearly 62% of overall distribution. Plasma-derived therapies are widely used in emergency medicine, hematology departments, transplant units, and intensive care facilities. Approximately 70% of albumin therapies are administered in hospital settings for treating trauma, shock, and liver failure. Additionally, around 60% of immunoglobulin treatments are delivered through hospital infusion centers. Globally, more than 120,000 hospitals provide plasma-derived therapeutic services, and about 45% of these hospitals are located in the Asia-Pacific region, reflecting expanding healthcare infrastructure.

Retail Pharmacy: Retail pharmacies represent approximately 25% of distribution within the Human Blood Plasma Fractionation Market Outlook and primarily supply maintenance therapies for chronic conditions. These pharmacies commonly distribute subcutaneous immunoglobulin treatments used by patients with primary immunodeficiency or autoimmune disorders. In developed healthcare systems, nearly 40% of long-term immunoglobulin therapies are supplied through retail pharmacy networks. More than 50,000 specialty pharmacies worldwide manage storage and dispensing of plasma-derived medicines. These pharmacies also support patient monitoring programs and therapy adherence systems, helping manage long-term treatment for thousands of patients requiring ongoing plasma protein therapies.

Others: Other application channels account for nearly 13% of the Human Blood Plasma Fractionation Market distribution, including specialty clinics, ambulatory care centers, and home healthcare services. Home-based immunoglobulin therapy has increased by approximately 28% over the past five years, particularly in North America and Europe where home infusion programs are expanding. Around 90,000 patients globally receive plasma-derived treatments through home infusion services, reducing the need for frequent hospital visits. Specialty clinics also administer coagulation factor therapies and rare disease treatments, improving access to plasma-derived therapeutics for patients requiring regular long-term care.

Regional Outlook

The Human Blood Plasma Fractionation Market Regional Outlook shows North America leading with about 46% market share, supported by over 1,000 plasma collection centers and more than 35 million liters of plasma processed annually. Europe holds nearly 28% share with around 300 collection facilities. Asia-Pacific represents about 19%, driven by 600+ plasma centers, while the Middle East & Africa contribute approximately 4%.

Download FREE Sample to learn more about this report.

North America

North America holds the largest position in the Human Blood Plasma Fractionation Market, accounting for nearly 46% of global market share and representing the most advanced plasma collection and processing ecosystem. The region processes more than 35 million liters of plasma annually, supported by an extensive network of over 1,000 plasma donation centers, most of which are located in the United States. The United States alone accounts for approximately 70% of the world’s plasma collection centers, enabling a stable supply of plasma used for manufacturing albumin, immunoglobulin, and coagulation factor therapies. Canada contributes nearly 5% of North America’s plasma supply, supported by approximately 50 plasma collection facilities distributed across several provinces.

Plasma-derived therapies are widely used across North America, with more than 250,000 patients receiving treatment annually for conditions such as primary immunodeficiency, hemophilia, neurological disorders, and liver diseases. The region also operates more than 15 large-scale plasma fractionation plants, each capable of processing between 1 million and 3 million liters of plasma per year, resulting in total production capacity exceeding 20 million liters annually. North America also leads in research and innovation within the Human Blood Plasma Fractionation Industry Analysis, hosting nearly 65% of global immunoglobulin clinical trials and more than 40 ongoing studies evaluating plasma-derived therapies for autoimmune and neurological conditions.

Europe

Europe represents approximately 28% of the Human Blood Plasma Fractionation Market Share, supported by a well-established healthcare infrastructure and a growing network of plasma collection centers. The region operates more than 300 plasma donation centers across countries including Germany, Austria, the Czech Republic, Hungary, and Spain. European fractionation plants collectively process nearly 12 million liters of plasma each year, producing therapeutic proteins such as immunoglobulins, albumin, and clotting factors used in treating rare diseases and immune disorders. Germany is one of the leading contributors to the European plasma supply, accounting for approximately 20% of the region’s total plasma collection volume.

Despite significant domestic production, Europe still relies on international plasma imports. Approximately 35% of plasma-derived medicinal products used in Europe are imported, mainly due to lower donation rates under voluntary donation systems compared with compensated donation models used elsewhere. Across Europe, more than 120,000 patients receive immunoglobulin therapy annually, while thousands of hemophilia patients depend on plasma-derived clotting factor concentrates. The region hosts over 10 major plasma fractionation manufacturers, operating advanced facilities capable of performing 8–12 purification steps to ensure high-quality plasma-derived therapies. Research institutions across Europe are also conducting more than 30 clinical research programs exploring new therapeutic applications for plasma proteins.

Asia-Pacific

Asia-Pacific accounts for approximately 19% of the Human Blood Plasma Fractionation Market Size and is rapidly expanding its plasma fractionation infrastructure to meet increasing healthcare demand. The region has over 600 plasma collection centers, supporting domestic plasma processing and therapeutic protein manufacturing. China is the largest contributor within the region, operating more than 30 licensed plasma fractionation companies and processing approximately 9 million liters of plasma annually. China’s plasma collection infrastructure has grown significantly, with more than 300 plasma collection stations supplying raw plasma for fractionation plants.

Japan contributes approximately 12% of Asia-Pacific plasma production, supported by advanced biotechnology facilities and strict regulatory oversight. South Korea also plays a growing role in the Human Blood Plasma Fractionation Market Outlook, operating around 5 major plasma fractionation plants and investing in improved purification technologies. Across the Asia-Pacific region, plasma-derived therapies are increasingly used to treat immune deficiencies, trauma cases, and liver diseases. Nearly 45% of global albumin consumption occurs in Asia-Pacific, primarily due to high rates of liver disease and hospital admissions in China and Southeast Asia. Governments across the region have also increased investments in plasma collection infrastructure by approximately 30% over the past five years, strengthening regional manufacturing capabilities.

Middle East & Africa

The Middle East & Africa account for approximately 4% of the Human Blood Plasma Fractionation Market Outlook, representing a developing region with growing healthcare demand but limited plasma processing infrastructure. The region processes approximately 1.5 million liters of plasma annually, with most fractionation activities concentrated in a small number of facilities. Countries such as Saudi Arabia and the United Arab Emirates operate approximately 3–4 plasma processing facilities, supporting local production of albumin and immunoglobulin therapies. Africa remains highly dependent on imports for plasma-derived medicinal products, with nearly 80% of plasma therapies imported from North America and Europe due to limited domestic fractionation capacity. \

Across the Middle East & Africa region, more than 50,000 patients require regular plasma-derived treatments for immune deficiencies, hemophilia, and neurological disorders. Several governments are now investing in local plasma collection programs to reduce import dependency. Between 2021 and 2024, investments in plasma donation and processing infrastructure in the Middle East increased by nearly 25%, leading to the establishment of new plasma collection centers and modernization of existing blood banks. Healthcare expansion programs across the region are also improving access to plasma therapies. Hospitals in the Middle East perform more than 15,000 plasma-based therapeutic procedures annually, while international partnerships are helping establish new fractionation technology programs aimed at improving regional production capacity.

Top Companies with Highest Market Share

• CSL – holds approximately 22% global market share, operating more than 300 plasma collection centers and processing nearly 10 million liters of plasma annually across 7 major fractionation facilities.
• Grifols – controls nearly 20% market share, managing over 390 plasma donation centers and producing more than 140 plasma-derived therapies distributed in over 100 countries.

Investment Analysis and Opportunities

Investment momentum in the Human Blood Plasma Fractionation Market has accelerated as global demand for plasma-derived therapeutics continues to expand across immunology, neurology, and hematology treatment areas. Between 2021 and 2024, more than 25 new plasma collection facilities were established globally, significantly increasing plasma supply capacity. Modern fractionation plants installed during this period are capable of processing between 1 million and 3 million liters of plasma per year, improving large-scale production of albumin, immunoglobulins, and coagulation factors. Global healthcare systems process approximately 55 million liters of plasma annually, and expansion of collection infrastructure is essential to meet increasing patient demand. Asia-Pacific has become a prominent investment hub within the Human Blood Plasma Fractionation Market Outlook.

China expanded its domestic plasma fractionation capacity by nearly 35% between 2020 and 2024, supported by more than 30 licensed plasma fractionation manufacturers operating nationwide. India has also increased plasma collection infrastructure by about 20%, adding new donation centers and expanding processing facilities. International biopharmaceutical companies are investing heavily in advanced purification technologies capable of improving protein extraction efficiency by 10%–15% per manufacturing cycle, enhancing production output without increasing plasma consumption. Infrastructure investments also include logistics systems for temperature-sensitive plasma products. Plasma-derived therapies must be transported within controlled storage ranges of 2°C to 8°C, prompting healthcare distributors to deploy more than 1,000 temperature-controlled storage units worldwide. Government programs in Europe and Asia are also promoting plasma donation initiatives targeting a 30% increase in voluntary plasma collection by 2030, which is expected to expand fractionation manufacturing opportunities and improve long-term plasma supply stability.

New Product Development

Innovation plays a critical role in strengthening the Human Blood Plasma Fractionation Market Growth, as manufacturers focus on developing safer and more efficient plasma-derived therapeutic products. Modern fractionation technologies now allow extraction of more than 12 distinct therapeutic proteins from a single plasma unit, compared with approximately 6–8 proteins extracted using traditional fractionation processes. Advanced purification technologies such as nanofiltration, affinity chromatography, and multiple viral inactivation procedures have improved plasma protein purity levels to over 99.5%, enhancing therapeutic safety and reducing risk of pathogen transmission. Immunoglobulin products represent the most active segment in new product development within the Human Blood Plasma Fractionation Market Trends. Currently, more than 40 immunoglobulin formulations are under clinical investigation globally for treatment of immune deficiencies and neurological disorders. Subcutaneous immunoglobulin therapies have become increasingly popular, accounting for nearly 30% of new plasma-derived therapy launches.

These treatments enable self-administration at home and have reduced hospital infusion visits by approximately 40%, improving patient convenience and healthcare efficiency. Manufacturers are also introducing advanced coagulation factor therapies designed for hemophilia treatment. New extended half-life clotting factor products reduce infusion frequency from about 3 injections per week to 1 injection per week, improving patient adherence to therapy. Albumin products are also evolving, with new formulations demonstrating storage stability for up to 36 months under regulated temperature conditions. Additionally, more than 20 global research programs are exploring plasma-derived therapeutic proteins for neurological diseases such as Alzheimer’s disease and autoimmune encephalitis, expanding the potential clinical applications of plasma fractionation technologies.

Five Recent Developments (2023-2025)

• In 2023, a major plasma manufacturer expanded its U.S. plasma collection network by adding 35 new donation centers, increasing annual plasma collection capacity by nearly 1.2 million liters.
• In 2024, a European fractionation facility upgraded purification technology, improving immunoglobulin yield by approximately 12% per production cycle.
• In 2023, a leading manufacturer introduced a new subcutaneous immunoglobulin therapy approved in over 30 countries for treating primary immunodeficiency disorders.
• In 2024, an Asia-Pacific biotechnology company expanded its fractionation plant capacity from 600,000 liters to 1.2 million liters annually, doubling albumin production.
• In 2025, a global plasma therapy producer initiated 5 clinical trials evaluating plasma-derived therapies for neurological disorders affecting more than 15,000 trial participants worldwide.

Report Coverage of Human Blood Plasma Fractionation Market

The Human Blood Plasma Fractionation Market Report delivers detailed insights into the global ecosystem of plasma-derived therapeutics, covering production, purification, processing, and supply chain distribution systems. The market structure includes more than 35 established manufacturers, supported by approximately 70 licensed plasma fractionation facilities and over 1,600 plasma collection centers worldwide. These facilities collectively process more than 55 million liters of plasma annually to extract essential therapeutic proteins. Key plasma-derived products examined in the Human Blood Plasma Fractionation Market Analysis include immunoglobulins, albumin, coagulation factors, fibrinogen, and alpha-1 antitrypsin, which are used in the treatment of over 100 rare and chronic medical conditions such as immune deficiencies, hemophilia, liver disease, and neurological disorders.

The Human Blood Plasma Fractionation Market Research Report also evaluates complex manufacturing processes that typically require 8 to 12 purification stages to ensure safety and therapeutic effectiveness. These stages include cold ethanol fractionation, chromatographic purification, nanofiltration, and viral inactivation procedures, each designed to maintain plasma protein purity levels exceeding 99%. The supply chain infrastructure supporting this market spans more than 120 countries, utilizing controlled cold-chain storage systems operating between 2°C and 8°C to preserve plasma stability during transport. Additionally, the Human Blood Plasma Fractionation Industry Analysis examines segmentation across product types, applications, and geographic regions including North America, Europe, Asia-Pacific, and Middle East & Africa, while highlighting technological advancements that improve protein extraction efficiency by 15%–20% through automated purification technologies.